Renaissance Technologies LLC Has $5.04 Million Position in AnaptysBio, Inc. $ANAB

Renaissance Technologies LLC raised its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 90,900 shares of the biotechnology company’s stock after buying an additional 14,600 shares during the period. Renaissance Technologies LLC’s holdings in AnaptysBio were worth $5,041,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC boosted its position in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after buying an additional 263 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 1,383 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in AnaptysBio by 987.3% during the 4th quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 1,560 shares during the last quarter.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $54.77 on Friday. The stock’s 50-day moving average is $57.46 and its 200 day moving average is $58.05. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -50.71 and a beta of 0.72.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. On average, sell-side analysts expect that AnaptysBio, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Zacks Research downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Barclays increased their price objective on AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Piper Sandler decreased their price target on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.00.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.